New Zealand Formulary
Menu Close Menu

Fewer cancers.
Better survival.
Equity for all.

Systemic Anti-Cancer Therapy Regimen Library

Home > CRC Metastatic - CETUximab [Q2W] and sotorasib

CRC Metastatic - CETUximab [Q2W] and sotorasib

Treatment Overview

Cycle 1 (and all further cycles) - 14 days

Cycle length:
14

Cycle details

Cycle 1 (and all further cycles) - 14 days

Medication Dose Route Days Max Duration
doxycycline * 100 mg Once daily oral administration 0
hydrocortisone * 1 % Once daily topical administration 0
cetostearyl alcohol + paraffin liquid + paraffin soft white 50 g Once daily topical administration 0
avobenzone + homosalate + octisalate + octocrilene + oxybenzone 50 g topical administration 0
dexamethasone * 8 mg oral administration 1
loratadine * 10 mg oral administration 1
sotorasib 960 mg Once daily oral administration 1 to 14
CETUximab * 500 mg/m² intravenous 1 120 minutes
loperamide 2 mg oral administration 1

Full details

Cycle 1 (and all further cycles) - 14 days

Day: 0

Medication Dose Route Max duration Details
doxycycline * 100 mg Once daily oral administration
Instructions:
  • To prevent rash.
  • Commence taking the day before cetuximab and continue for 6 weeks or as per institutional policy. If no rash develops after 6 weeks, consider stopping.
  • Take each dose with food and a large glass of water. Swallow whole, do not crush or chew. Remain sitting upright or standing for at least 30 minutes afterwards. Do not take indigestion remedies, iron or calcium preparations within 2 hours of taking this medicine.
  • Protect yourself from too much natural or artificial sunlight while being treated with this medicine.
hydrocortisone * 1 % Once daily topical administration
Instructions:
  • To prevent rash.
  • Apply to the face, hands, feet, neck, back and chest at bedtime or as directed by your oncologist.
  • If no rash develops after 6 weeks, consider stopping.
cetostearyl alcohol + paraffin liquid + paraffin soft white 50 g Once daily topical administration
Instructions:
  • Apply as a moisturiser to the face, hands, feet, neck, back and chest each morning or as directed by your oncologist.
  • Whilst this is a subsidised preparation, other moisturisers may also be suitable.
  • Quantity is approximate only, prescriber discretion required.
avobenzone + homosalate + octisalate + octocrilene + oxybenzone 50 g topical administration
Instructions:
  • SPF 50+ Sunscreen—apply to skin 30 minutes before going outdoors as directed by your oncologist.
  • Certified condition for subsidy. Whilst this is the subsidised preparation, alternative SPF 50+ sunscreen preparations may also be suitable.
  • Quantity is approximate only, prescriber discretion required.

Day: 1

Medication Dose Route Max duration Details
dexamethasone * 8 mg oral administration
Instructions:

ONE hour prior to cetuximab with food.
    loratadine * 10 mg oral administration
    Instructions:

    ONE hour prior to cetuximab.
      sotorasib 960 mg Once daily oral administration
      Instructions:
      • Swallow whole with a glass of water, do not crush, chew or split tablets.
      • For patients unable to swallow tablets, see product literature.
      CETUximab * 500 mg/m² intravenous 120 minutes
      Instructions:
      • Administer over 120 minutes; if initial and all previous doses are well tolerated, evidence from clinical trials support administration of subsequent doses over 60 minutes.
      • An observation period of 60 minutes post-infusion is recommended.
      loperamide 2 mg oral administration
      Instructions:
      Take TWO capsules (=4 mg) at onset of loose bowel motions and a further ONE capsule (=2 mg) for every loose bowel motion (maximum of EIGHT capsules in 24 hours), or use as directed by oncologist or haematologist.

      Day: 2

      Medication Dose Route Max duration Details
      sotorasib 960 mg Once daily oral administration
      Instructions:
      • Swallow whole with a glass of water, do not crush, chew or split tablets.
      • For patients unable to swallow tablets, see product literature.

      Day: 3

      Medication Dose Route Max duration Details
      sotorasib 960 mg Once daily oral administration
      Instructions:
      • Swallow whole with a glass of water, do not crush, chew or split tablets.
      • For patients unable to swallow tablets, see product literature.

      Day: 4

      Medication Dose Route Max duration Details
      sotorasib 960 mg Once daily oral administration
      Instructions:
      • Swallow whole with a glass of water, do not crush, chew or split tablets.
      • For patients unable to swallow tablets, see product literature.

      Day: 5

      Medication Dose Route Max duration Details
      sotorasib 960 mg Once daily oral administration
      Instructions:
      • Swallow whole with a glass of water, do not crush, chew or split tablets.
      • For patients unable to swallow tablets, see product literature.

      Day: 6

      Medication Dose Route Max duration Details
      sotorasib 960 mg Once daily oral administration
      Instructions:
      • Swallow whole with a glass of water, do not crush, chew or split tablets.
      • For patients unable to swallow tablets, see product literature.

      Day: 7

      Medication Dose Route Max duration Details
      sotorasib 960 mg Once daily oral administration
      Instructions:
      • Swallow whole with a glass of water, do not crush, chew or split tablets.
      • For patients unable to swallow tablets, see product literature.

      Day: 8

      Medication Dose Route Max duration Details
      sotorasib 960 mg Once daily oral administration
      Instructions:
      • Swallow whole with a glass of water, do not crush, chew or split tablets.
      • For patients unable to swallow tablets, see product literature.

      Day: 9

      Medication Dose Route Max duration Details
      sotorasib 960 mg Once daily oral administration
      Instructions:
      • Swallow whole with a glass of water, do not crush, chew or split tablets.
      • For patients unable to swallow tablets, see product literature.

      Day: 10

      Medication Dose Route Max duration Details
      sotorasib 960 mg Once daily oral administration
      Instructions:
      • Swallow whole with a glass of water, do not crush, chew or split tablets.
      • For patients unable to swallow tablets, see product literature.

      Day: 11

      Medication Dose Route Max duration Details
      sotorasib 960 mg Once daily oral administration
      Instructions:
      • Swallow whole with a glass of water, do not crush, chew or split tablets.
      • For patients unable to swallow tablets, see product literature.

      Day: 12

      Medication Dose Route Max duration Details
      sotorasib 960 mg Once daily oral administration
      Instructions:
      • Swallow whole with a glass of water, do not crush, chew or split tablets.
      • For patients unable to swallow tablets, see product literature.

      Day: 13

      Medication Dose Route Max duration Details
      sotorasib 960 mg Once daily oral administration
      Instructions:
      • Swallow whole with a glass of water, do not crush, chew or split tablets.
      • For patients unable to swallow tablets, see product literature.

      Day: 14

      Medication Dose Route Max duration Details
      sotorasib 960 mg Once daily oral administration
      Instructions:
      • Swallow whole with a glass of water, do not crush, chew or split tablets.
      • For patients unable to swallow tablets, see product literature.

      Supportive Care Factors

      Factor Value
      Diarrhoea risk: Anti-diarrhoeals are usually prescribed with this treatment
      Emetogenicity: Minimal to low
      Hypersensitivity / Infusion related reaction risk: High - routine premedication recommended

      Emetogenicity: MINIMAL to LOW—Routine antiemetic premedication is not usually required; an individualised approach is appropriate. 

      References

      Fakih MG, Salvatore L, Esaki T, et al. Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated KRAS G12C. N Engl J Med. 2023 Dec 7;389(23):2125-2139. , PMID: 37870968

      Amgen Limited. LUMYKRAS United Kingdom Summary of Product Characteristics. 18 September 2025. https://mhraproducts4853.blob.core.windows.net/docs/98e887d3b3f0d279eaa65c17c544beafa9ce40e2 (Accessed 12 February 2026).

      Healthcare Logistics Ltd. Erbitux New Zealand Data Sheet 30 January 2024. https://www.medsafe.govt.nz/profs/Datasheet/e/Erbituxinf.pdf (Accessed 12 February 2026).

      Hofheinz RD, Deplanque G, Komatsu Y, et al. Recommendations for the Prophylactic Management of Skin Reactions Induced by Epidermal Growth Factor Receptor Inhibitors in Patients With Solid Tumors. Oncologist. 2016;21(12):1483-1491., PMID: 27449521

      Lacouture ME, Anadkat MJ, Bensadoun RJ, Bryce J, Chan A, Epstein JB, Eaby-Sandy B, Murphy BA; MASCC Skin Toxicity Study Group. Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities. Support Care Cancer. 2011 Aug;19(8):1079-95., PMID: 21630130

      Deplanque, Gaël, et al. “Doxycycline for prevention of erlotinib-induced rash in patients with non-small-cell lung cancer (NSCLC) after failure of first-line chemotherapy: A randomized, open-label trial”. Journal of the American Academy of Dermatology. 2016 Jun 1;74.6 (2016):1077-85., PMID: 26946985

      Dika, E. and Patrizi, A. “Prevention of erlotinib-induced folliculitis with doxycycline”. Dermatologic therapy, 30.1 (2017): e12419., PMID: 27592506

      Regimen details sometimes vary slightly from the published literature after recommendation by expert committee consensus.

      * The medicines, doses, combinations, and schedule in this treatment regimen have been carefully reviewed against international best practice guidelines by specialists in medical oncology around New Zealand and this advice has been accepted for publication by Te Aho o Te Kahu (the Cancer Control Agency). Sometimes medicines that are used in routine clinical practice have not been through a formal review process by the NZ Medicines Regulator Medsafe and are therefore considered unapproved or off-label. These medicines are legally able to be prescribed through sections 25 and 29 of the Medicines Act and by obtaining informed consent from patients. All treatment regimens listed on this website have been through robust peer review and are considered an accepted standard of care, whether prescribed through sections 25 or 29 or carrying formal Medsafe Approval.

      s29: This symbol indicates that some formulations of the associated medicine are legally only able to be prescribed under section 29 of the Medicines Act. You can see which formulations are section 29 by hovering over the s29 symbol. You can access full medication details from the New Zealand Formulary by clicking on the medication name. Each clinician retains full responsibility for ensuring they have complied with all relevant obligations and requirements of section 29 including obtaining informed patient consent prior to prescribing the applicable medicine.